Efficacy and safety of Tenofovir Disoproxil Fumarate in Egyptian patients with chronic hepatitis B virus infection | ||
| Journal of Medical and Life Science | ||
| Volume 6, Issue 1, March 2024, Pages 20-32 PDF (1.2 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jmals.2024.260653.1016 | ||
| Authors | ||
| Othman Ali Othman* 1; Sahar Sayed Kamal2 | ||
| 1Chemistry department (Biochemistry Division)-Faculty of Science-Minia University-ElMinia-Egypt | ||
| 2Malawi Specialized Hospital (Laboratory Department) Malawi, Minia, Egypt | ||
| Abstract | ||
| Background: Hepatitis B virus (HBV) infection is a major global health problem leading to severe liver diseases such as cirrhosis and hepatocellular carcinoma. Tenofovir Disoproxil Fumarate (TDF) is an orally bioavailable prodrug of Tenofovir. This study aimed to evaluate the efficacy and safety of long-term TDF therapy in Egyptian Chronic Hepatitis B patients, Objective: Assessment of effectiveness and safety of TDF therapy in Egyptian HBV patients. Materials and Methods: HBV was confirmed by detection of both HBsAg and HBV DNA. All patients were given antiviral drug (300 mg TDF, oral, once a day for 3 months). Results: Before treatment; HBV Patients showed significant elevation in Ferritin, Albumin, S. Creatinine, AST, ALT, PO4, INR, and PT compared to the healthy volunteers’ group. Additionally showed a decrease in AFP, DB, TB, PC, PLT, and WBCs again in comparison to the control group. After receiving HBV TDF, the same group of patients showed a significant increase in Ferritin, S. Creatinine, TB, PC, WBCs, and Hb% and a significant decrease in PO4, Albumin, INR, and PT compared to pre-treatment conditions. Conclusion: we show clear benefits of TDF therapy in ethnically diverse CHB populations, even among patients with only mild/moderate liver disease at baseline. | ||
| Keywords | ||
| Hepatitis B virus; Tenofovir Disoproxil Fumarate; Alfa fetoprotein; Ferritin; liver enzymes | ||
|
Statistics Article View: 330 PDF Download: 171 |
||
